Ph 1 trials for TLN-121, TLN-254 in lymphoma and TLN-372 in patients with cancers expressing certain KRAS mutations initiated September 9, 2025
HERTHENA-Breast04 Ph 3 Trial of Patritumab Deruxtecan Initiated for Metastatic HR+ve, HER2-neg Breast Cancer Previously Treated with Endocrine Therapy September 3, 2025
Clinical development of ZW171 to be discontinued in gynecological, thoracic, and digestive system cancers September 3, 2025
First Patient Dosed in Expansion Cohorts of Ph 1/2 SOLARA Trial of BH-30643 in Advanced EGFRm NSCLC September 3, 2025
First cohort in Ph 1 trial of 177Lu-AKIR001 completed in patients with solid tumors September 3, 2025
SAKK 66/17 Ph 1b/2a Clinical Trial of IP-001 for Treatment of Solid Tumors Completed September 3, 2025
First Patient Dosed in Pivotal Ph 3 Trial of Cadonilimab for Perioperative Treatment of Resectable Gastric Cancer August 26, 2025
First Patient Dosed in Ph 1 inMMyCAR Study of in vivo CAR T-cell Therapy for RRMM patients August 26, 2025
First patient dosed in registrational clinical trial of mesutoclax for the treatment of BTKi-experienced mantle cell lymphoma in China August 26, 2025
First Patient Dosed in Expansion Cohorts of Ph 1/2 SOLARA Trial of BH-30643 in Advanced EGFRm NSCLC August 26, 2025
Enrollment paused in Ph 1/2 OPAL-1 trial of intratumoral KB707 in solid tumors, prioritizing work on inhaled KB707 in NSCLC August 26, 2025
Patient deaths trigger discontinuation of Ph 1 trial from SGR-2921 Program in R/R AML and HR-MDS patients August 19, 2025
Further development of PRT3789 in patients with biomarker selected SMARCA4-mutated cancers paused August 19, 2025
First Patient Dosed in Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs August 19, 2025
CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses August 19, 2025
Positive Recommendation by IDMC Announced: ELI-002 7P Ph 2 Study in Pancreatic Cancer to Continue Without Modifications to Final Analysis August 12, 2025
First Patient Dosed in Ph 3 Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy August 12, 2025
First Patient Dosed in Ph 1 Trial of ATV-1601 in Patients with AKT1 E17K-mutant Solid Tumors August 12, 2025
